Navigation Links
Chemo Plus Synthetic Drug Shrunk Pancreatic Tumors
Date:3/25/2010

Research with mice might one day yield new therapies, study says

THURSDAY, March 25 (HealthDay News) -- When used with chemotherapy, an experimental synthetic drug called JP1201 was effective against human pancreatic cancer in mice, a new study found.

JP1201 mimics that action of a naturally occurring protein (Smac) that triggers cell death.

In this study, researchers gave JP1201 and the chemotherapy drug gemcitabine to mice with transplanted human pancreatic tumors.

"There was a 50 percent regression in tumor size during a two-week treatment of the mice," study senior author Dr. Rolf Brekken, an associate professor of surgery and pharmacology at the University of Texas Southwestern Medical Center in Dallas, said in a news release from the medical center.

The combination treatment also prolonged the life of the mice. The finding could lead to more effective therapies for pancreatic and possibly other cancers, the researchers said.

The study was published March 23 in the journal Cancer Research.

"This compound enhanced the efficacy of chemotherapy and improved survival in multiple animal models of pancreatic cancer. We now have multiple lines of evidence in animals showing that this combination is having a potent effect on pancreatic cancer, which is a devastating disease," Brekken said.

The research was supported by Joyant Pharmaceuticals, a Dallas-based company and UT Southwestern spinoff that's developing medical applications of compounds that mimic that action of the Smac protein.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: UT Southwestern Medical Center, news release, March 23, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chemo May Boost Survival After Lung Cancer Surgery
2. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
3. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
6. Are New Chemo Treatments Cost-Effective?
7. Older Colon Cancer Patients Less Likely to Get Chemo
8. Study evaluates costs and benefits of new chemotherapy drugs
9. Scientists identify microRNA as possible cause of chemotherapy resistance
10. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
11. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: